go Contents

Global Business / A key SAMA priority is build winning collaborations

Global Business

  • KGMP factory movie : State-of-the art clean area EU Standard KGMP factory to introduce

Licensing opportunity

HOME Global Business Licensing opportunity

SAMA offers a wide range of Regulatory, R&D, Manufacturing and In&Out Licensing services

1.Our Services

SAMA offers a wide range of Regulatory, R&D, Manufacturing and In&Out Licensing services as follows:-R&D and Product Development, -Dossier Development, -In&Out Licensing, -Commercial supplies, -Manufacture in Finished dosage(tablets, granules, external Liquids, oral Liquids)

2.In-Licensing

We're focused on leveraging external compound innovation and capabilities around the world. We have dedicated an organization and system to work with our partners and for successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to pharmaceutical companies. Our main goal is to bring innovation from partnership to patients. We seek products that can leverage our core strengths and complement our existing product portfolio in the following therapy area: -Allergy, Asthma & COPD, -Respiratory,-Dermatology. We search for innovative compounds and biomedicals at all stages of development. We seek to establish a long term, mutually rewarding relationship and open to the full range of set-ups from in-licensing to strategic alliances for co-development.

3.Out-Licensing

SAMA is actively seeking out-licensing opportunities for VIASIN® granules. VIASIN® is the world’s first granule form of Sidenafil freebase, which was made possible by SAMA’s innovative DDS technology, IDIA™(Instant Dissolving Immediate Absorption). VIASIN® unique characteristics are as follows:(1) Easy to carry around in a thin paper sachet package, (2) Dissolves immediately in your mouth without residue,(3) Absorbed more quickly than tablet forms. We are now adding new pipelines with innovative IDIA™ technology.